| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected and Quantified |
|---|
| Creation Date | 2005-11-16 15:48:42 UTC |
|---|
| Update Date | 2022-03-07 02:49:01 UTC |
|---|
| HMDB ID | HMDB0000365 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Epiandrosterone |
|---|
| Description | Epiandrosterone is a naturally occurring steroid synthesized in the adrenal cortex, gonads, brain, and gastrointestinal tract. It is less active than androsterone and excreted in small amounts in normal human urine. Epiandrosterone is a metabolite of the most abundant adrenal androgenic steroid dehydroepiandrosterone (DHEA) in young adult humans, but is not completely inactive and is considered an effector as well. Epiandrosterone is a precursor or substrate for cytochrome P450 species and enzymes (EC 1.14.13.100, 25-hydroxycholesterol 7alpha-hydroxylase) that produce 7alpha- and 7beta-hydroxylated metabolites in the human brain and other organs. These 7-hydroxylated derivatives exert anti-glucocorticoid and neuroprotective effects (PMID: 17017935 , 12475725 , 15650074 , 15784286 ). |
|---|
| Structure | [H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2C[C@@H](O)CC[C@]12C InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12-16,20H,3-11H2,1-2H3/t12?,13-,14-,15-,16-,18-,19-/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| 3-Epiandrosterone | HMDB | | 3b-Androsterone | HMDB | | 3b-Hydroxy-17-oxo-5a-androstane | HMDB | | 3b-Hydroxy-5a-androstan-17-one | HMDB | | 3b-Hydroxy-5a-androstane-17-one | HMDB | | 3b-Hydroxyandrostan-17-one | HMDB | | 3b-Hydroxyetioallocholan-17-one | HMDB | | 3b-OH-5a-Androstane-17-one | HMDB | | 5a-Androstan-3b-ol-17-one | HMDB | | 5a-Androstane-3b-ol-17-one | HMDB | | D-Epiandrosterone | HMDB | | Epi-andosterone | HMDB | | Epi-androsterone | HMDB | | Iso-androsterone | HMDB | | Isoandrosterone | HMDB | | trans-Androsterone | HMDB | | (3Β,5α)-3-hydroxyandrostan-17-one | HMDB | | 3Β-androsterone | HMDB | | 3Β-hydroxy-17-oxo-5α-androstane | HMDB | | 3Β-hydroxy-5α-androstan-17-one | HMDB | | 3Β-hydroxy-5α-androstane-17-one | HMDB | | 3Β-hydroxyandrostan-17-one | HMDB | | 3Β-hydroxyetioallocholan-17-one | HMDB | | 3Β-OH-5α-androstane-17-one | HMDB | | 5Α-androstan-17-one-3β-ol | HMDB | | 5Α-androstan-3β-ol-17-one | HMDB | | 5Α-androstane-3β-ol-17-one | HMDB | | (3beta,5alpha)-3-Hydroxyandrostan-17-one | HMDB | | 3beta-Androsterone | HMDB | | 3beta-Hydroxy-17-oxo-5alpha-androstane | HMDB | | 3beta-Hydroxy-5alpha-androstan-17-one | HMDB | | 3beta-Hydroxy-5alpha-androstane-17-one | HMDB | | 3beta-Hydroxyandrostan-17-one | HMDB | | 3beta-Hydroxyetioallocholan-17-one | HMDB | | 3beta-OH-5alpha-Androstane-17-one | HMDB | | 5alpha-Androstan-17-one-3beta-ol | HMDB | | 5alpha-Androstan-3beta-ol-17-one | HMDB | | 5alpha-Androstane-3beta-ol-17-one | HMDB |
|
|---|
| Chemical Formula | C19H30O2 |
|---|
| Average Molecular Weight | 290.4403 |
|---|
| Monoisotopic Molecular Weight | 290.224580204 |
|---|
| IUPAC Name | (1S,2S,5S,10R,11S,15S)-5-hydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-one |
|---|
| Traditional Name | (1S,2S,5S,10R,11S,15S)-5-hydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-one |
|---|
| CAS Registry Number | 481-29-8 |
|---|
| SMILES | [H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2C[C@@H](O)CC[C@]12C |
|---|
| InChI Identifier | InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12-16,20H,3-11H2,1-2H3/t12?,13-,14-,15-,16-,18-,19-/m0/s1 |
|---|
| InChI Key | QGXBDMJGAMFCBF-QRIARFFBSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Steroids and steroid derivatives |
|---|
| Sub Class | Androstane steroids |
|---|
| Direct Parent | Androgens and derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - Androgen-skeleton
- 3-hydroxysteroid
- 3-beta-hydroxysteroid
- Oxosteroid
- 17-oxosteroid
- Hydroxysteroid
- Cyclic alcohol
- Secondary alcohol
- Ketone
- Organic oxygen compound
- Organooxygen compound
- Hydrocarbon derivative
- Carbonyl group
- Organic oxide
- Alcohol
- Aliphatic homopolycyclic compound
|
|---|
| Molecular Framework | Aliphatic homopolycyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Ontology |
|---|
| Physiological effect | |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 178 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.02 mg/mL at 23 °C | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 6.74 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 15.9518 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.51 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2548.1 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 411.2 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 206.9 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 189.8 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 494.0 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 642.8 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 656.7 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 106.1 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1266.1 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 454.8 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1493.2 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 368.6 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 428.2 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 294.1 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 415.8 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 23.6 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Epiandrosterone,1TMS,isomer #1 | C[C@]12CC[C@H]3[C@@H](CCC4C[C@@H](O[Si](C)(C)C)CC[C@@]43C)[C@@H]1CCC2=O | 2578.5 | Semi standard non polar | 33892256 | | Epiandrosterone,1TMS,isomer #2 | C[C@]12CC[C@H]3[C@@H](CCC4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2O[Si](C)(C)C | 2579.0 | Semi standard non polar | 33892256 | | Epiandrosterone,2TMS,isomer #1 | C[C@]12CC[C@H]3[C@@H](CCC4C[C@@H](O[Si](C)(C)C)CC[C@@]43C)[C@@H]1CC=C2O[Si](C)(C)C | 2602.6 | Semi standard non polar | 33892256 | | Epiandrosterone,2TMS,isomer #1 | C[C@]12CC[C@H]3[C@@H](CCC4C[C@@H](O[Si](C)(C)C)CC[C@@]43C)[C@@H]1CC=C2O[Si](C)(C)C | 2511.5 | Standard non polar | 33892256 | | Epiandrosterone,2TMS,isomer #1 | C[C@]12CC[C@H]3[C@@H](CCC4C[C@@H](O[Si](C)(C)C)CC[C@@]43C)[C@@H]1CC=C2O[Si](C)(C)C | 2920.4 | Standard polar | 33892256 | | Epiandrosterone,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)O[C@H]1CC[C@@]2(C)C(CC[C@H]3[C@@H]4CCC(=O)[C@@]4(C)CC[C@@H]32)C1 | 2818.4 | Semi standard non polar | 33892256 | | Epiandrosterone,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC1=CC[C@H]2[C@@H]3CCC4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C | 2849.6 | Semi standard non polar | 33892256 | | Epiandrosterone,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1=CC[C@H]2[C@@H]3CCC4C[C@@H](O[Si](C)(C)C(C)(C)C)CC[C@]4(C)[C@H]3CC[C@]12C | 3134.5 | Semi standard non polar | 33892256 | | Epiandrosterone,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1=CC[C@H]2[C@@H]3CCC4C[C@@H](O[Si](C)(C)C(C)(C)C)CC[C@]4(C)[C@H]3CC[C@]12C | 2771.5 | Standard non polar | 33892256 | | Epiandrosterone,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1=CC[C@H]2[C@@H]3CCC4C[C@@H](O[Si](C)(C)C(C)(C)C)CC[C@]4(C)[C@H]3CC[C@]12C | 3167.0 | Standard polar | 33892256 |
|
|---|
| General References | - Mitamura K, Setaka M, Shimada K, Honma S, Namiki M, Koh E, Mizokami A: Determination of sulfates of androsterone and epiandrosterone in human serum using isotope diluted liquid chromatography-electrospray ionization-mass spectrometry. Biomed Chromatogr. 2005 Dec;19(10):796-801. [PubMed:15954157 ]
- Chalbot S, Morfin R: Human liver S9 fractions: metabolism of dehydroepiandrosterone, epiandrosterone, and related 7-hydroxylated derivatives. Drug Metab Dispos. 2005 Apr;33(4):563-9. Epub 2005 Jan 13. [PubMed:15650074 ]
- Johnson MD, Bebb RA, Sirrs SM: Uses of DHEA in aging and other disease states. Ageing Res Rev. 2002 Feb;1(1):29-41. [PubMed:12039447 ]
- Norman RJ, Maharaj C, Adhikari M, Joubert SM: Adrenal sensitivity to adrenocorticotrophin in twin neonates--effect of birth order and growth retardation. S Afr Med J. 1984 Jul 21;66(3):90-2. [PubMed:6330917 ]
- Hungerford NL, Sortais B, Smart CG, McKinney AR, Ridley DD, Stenhouse AM, Suann CJ, Munn KJ, Sillence MN, McLeod MD: Analysis of anabolic steroids in the horse: development of a generic ELISA for the screening of 17alpha-alkyl anabolic steroid metabolites. J Steroid Biochem Mol Biol. 2005 Aug;96(3-4):317-34. [PubMed:16040239 ]
- Thijssen JH, Daroszewski J, Milewicz A, Blankenstein MA: Local aromatase activity in human breast tissues. J Steroid Biochem Mol Biol. 1993 Mar;44(4-6):577-82. [PubMed:8476769 ]
- Matsuzaki Y, Honda A: Dehydroepiandrosterone and its derivatives: potentially novel anti-proliferative and chemopreventive agents. Curr Pharm Des. 2006;12(26):3411-21. [PubMed:17017935 ]
- Yoshida S, Honda A, Matsuzaki Y, Fukushima S, Tanaka N, Takagiwa A, Fujimoto Y, Miyazaki H, Salen G: Anti-proliferative action of endogenous dehydroepiandrosterone metabolites on human cancer cell lines. Steroids. 2003 Jan;68(1):73-83. [PubMed:12475725 ]
- Chalbot S, Morfin R: Neurosteroids: metabolism in human intestine microsomes. Steroids. 2005 Apr;70(4):319-26. [PubMed:15784286 ]
|
|---|